| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Priority Reports |
Transactivates HER2-neu in Breast Cancer Cells by a Novel Pathway Involving Src Kinase Activation
Departments of 1 Cancer Biology and 2 Pathology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas; 3 Department of Pathology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey; and 4 Center for Cell Biology and Cancer Research, Albany Medical College, Albany, New York
Requests for reprints: Janet E. Price, Department of Cancer Biology, Unit 173, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030. Phone: 713-563-5484; Fax: 713-792-8747; E-mail: jprice{at}mdanderson.org.
Experimental evidence suggests that CXCR4, a Gi proteincoupled receptor for the ligand CXCL12/stromal cellderived factor-1
(SDF-1
), plays a role in breast cancer metastasis. Transactivation of HER2-neu by G proteincoupled receptor activation has been reported as a ligand-independent mechanism of activating tyrosine kinase receptors. We found that SDF-1
transactivated HER2-neu in the breast cancer cell lines MDA-MB-361 and SKBR3, which express both CXCR4 and HER2-neu. AMD3100, a CXCR4 inhibitor, PKI 166, an epidermal growth factor receptor/HER2-neu tyrosine kinase inhibitor, and PP2, a Src kinase inhibitor, each blocked SDF-1
induced HER2-neu phosphorylation. Blocking Src kinase, with PP2 or using a kinase-inactive Src construct, and inhibiting epidermal growth factor receptor/HER2-neu signaling with PKI 166 each inhibited SDF-1
stimulated cell migration. We report a novel mechanism of HER2-neu transactivation through SDF-1
stimulation of CXCR4 that involves Src kinase activation.
This article has been cited by other articles:
![]() |
K.-K. Kim, J. J. Lee, Y. Yang, K.-H. You, and J.-H. Lee Macrophage inhibitory cytokine-1 activates AKT and ERK-1/2 via the transactivation of ErbB2 in human breast and gastric cancer cells Carcinogenesis, April 1, 2008; 29(4): 704 - 712. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. R. Chinni, H. Yamamoto, Z. Dong, A. Sabbota, R. D. Bonfil, and M. L. Cher CXCL12/CXCR4 Transactivates HER2 in Lipid Rafts of Prostate Cancer Cells and Promotes Growth of Metastatic Deposits in Bone Mol. Cancer Res., March 1, 2008; 6(3): 446 - 457. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Pattarozzi, M. Gatti, F. Barbieri, R. Wurth, C. Porcile, G. Lunardi, A. Ratto, R. Favoni, A. Bajetto, A. Ferrari, et al. 17 -Estradiol Promotes Breast Cancer Cell Proliferation-Inducing Stromal Cell-Derived Factor-1-Mediated Epidermal Growth Factor Receptor Transactivation: Reversal by Gefitinib Pretreatment Mol. Pharmacol., January 1, 2008; 73(1): 191 - 202. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Miao, K. E. Luker, B. C. Summers, R. Berahovich, M. S. Bhojani, A. Rehemtulla, C. G. Kleer, J. J. Essner, A. Nasevicius, G. D. Luker, et al. CXCR7 (RDC1) promotes breast and lung tumor growth in vivo and is expressed on tumor-associated vasculature PNAS, October 2, 2007; 104(40): 15735 - 15740. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Patrussi, C. Ulivieri, O. M. Lucherini, S. R. Paccani, A. Gamberucci, L. Lanfrancone, P. G. Pelicci, and C. T. Baldari p52Shc is required for CXCR4-dependent signaling and chemotaxis in T cells Blood, September 15, 2007; 110(6): 1730 - 1738. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. A. Begley, J. W. MacDonald, M. L. Day, and J. A. Macoska CXCL12 Activates a Robust Transcriptional Response in Human Prostate Epithelial Cells J. Biol. Chem., September 14, 2007; 282(37): 26767 - 26774. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Uchida, T. Onoue, Y. Tomizuka, N. M. Begum, Y. Miwa, H. Yoshida, and M. Sato Involvement of an Autocrine Stromal Cell Derived Factor-1/CXCR4 System on the Distant Metastasis of Human Oral Squamous Cell Carcinoma Mol. Cancer Res., July 1, 2007; 5(7): 685 - 694. [Abstract] [Full Text] [PDF] |
||||
![]() |
N Cabioglu, Y Gong, R Islam, K. Broglio, N Sneige, A Sahin, A. Gonzalez-Angulo, P Morandi, C Bucana, G. Hortobagyi, et al. Expression of growth factor and chemokine receptors: new insights in the biology of inflammatory breast cancer Ann. Onc., June 1, 2007; 18(6): 1021 - 1029. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Xu, X. Yuan, K. Beebe, Z. Xiang, and L. Neckers Loss of Hsp90 Association Up-Regulates Src-Dependent ErbB2 Activity Mol. Cell. Biol., January 1, 2007; 27(1): 220 - 228. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Gabos, R. Sinha, J. Hanson, N. Chauhan, J. Hugh, J. R. Mackey, and B. Abdulkarim Prognostic Significance of Human Epidermal Growth Factor Receptor Positivity for the Development of Brain Metastasis After Newly Diagnosed Breast Cancer J. Clin. Oncol., December 20, 2006; 24(36): 5658 - 5663. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Luo, H. Pan, M. Mines, K. Watson, J. Zhang, and G.-H. Fan CXCL12 Induces Tyrosine Phosphorylation of Cortactin, Which Plays a Role in CXC Chemokine Receptor 4-mediated Extracellular Signal-regulated Kinase Activation and Chemotaxis J. Biol. Chem., October 6, 2006; 281(40): 30081 - 30093. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |